![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1477059
¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç°/¼Ö·ç¼Ç, ±â¼ú, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global 3D Bioprinting in Medical Market Size study, by Products and Solutions by Technology, by Application, by End User and Regional Forecasts 2022-2032 |
¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀåÀº 2023³â ¾à 12¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 15.5% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃÀº Á¶Á÷°øÇÐ ¹× Àç»ýÀÇ·á¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀÔ´Ï´Ù. »ýü Àç·á, ¼¼Æ÷, ¼ºÀå ÀÎÀÚ¸¦ Ãþº°·Î Á¤È®ÇÏ°Ô ÁõÂøÇÏ¿© ¿ø·¡ Á¶Á÷°ú Àå±âÀÇ º¹ÀâÇÑ ±¸Á¶¿Í ±â´ÉÀ» ¸ð¹æÇÑ 3Â÷¿ø ±¸Á¶¸¦ »ý¼ºÇÏ´Â ±â¼úÀÔ´Ï´Ù. ÀÌ ÃÖ÷´Ü ±â¼úÀº Àå±â À̽Ä, ¾à¹° ½ºÅ©¸®´×, Áúº´ ¸ðµ¨¸µ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á µî ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß¿¡ Å« ±â´ë¸¦ ¸ðÀ¸°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀåÀÇ Æ®·»µå´Â ÀÌÁ¾ ¼ººÐÀÇ º¹ÀâÇÑ Á¶Á÷ ±¸Á¶¸¦ »ý¼ºÇÒ ¼ö ÀÖ´Â ´ÙÀç·á, ´Ù¼¼Æ÷ ÇÁ¸°ÆÃÀ¸·Î ÇâÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ¼¼Æ÷ À¯Çü°ú »ýü Àç·á¸¦ ÇÁ¸°ÆÃ °øÁ¤¿¡ ÅëÇÕÇÔÀ¸·Î½á ¿¬±¸ÀÚµéÀº ¿ø·¡ÀÇ Á¶Á÷°ú ±â°ü¿¡¼ ¹ß°ßµÇ´Â ´Ù¾çÇÑ ¹Ì¼¼ ȯ°æÀ» ¸ð¹æÇÏ¿© ±¸Á¶¹°ÀÇ ±â´É¼º°ú »ý¹°ÇÐÀû °ü·Ã¼ºÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀåÀº ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÈûÀÔ¾î °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¸¸¼º ÁúȯÀÇ È®»ê°ú ´õºÒ¾î Áúº´ ÁøÇàÀ» ¿¬±¸Çϰí Ç¥Àû Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ º¸´Ù Á¤È®ÇÑ ¸ðµ¨¸µÀÌ Àý½ÇÈ÷ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â Áúº´ ¸ðµ¨¸µ ¹× ¾à¹° Å×½ºÆ® ¿ëµµ¿¡¼ 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Advanced Regenerative Manufacturing Institute(ARMI)´Â ÁÖ¿ä Á¦Á¶¾÷ü, ´ëÇÐ, ºñ¿µ¸® ´Üü ¹× ¿¬¹æ Á¤ºÎ·ÎºÎÅÍ 3¾ï ´Þ·¯ ÀÌ»óÀÇ ¸·´ëÇÑ ÅõÀÚ¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ÀÚ±ÝÀº Àΰø Á¶Á÷ ¹× Àå±âÀÇ È®Àå °¡´ÉÇÑ Á¦Á¶ °øÁ¤ °³¹ßÀ» ÃËÁøÇϱâ À§ÇÑ °ÍÀ¸·Î, 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ±â¼ú ¹ßÀü¿¡ ´ëÇÑ ¾÷°èÀÇ ³ë·ÂÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼°è ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀåÀº 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ±â¼úÀÇ ¹ßÀü°ú ÀÇ·á ¿¬±¸ ¹× °³¹ß Ȱµ¿¿¡ ´ëÇÑ ÁöÃâ Áõ°¡¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Á¶Á÷ °øÇÐÀÇ º¹À⼺°ú 3D ¹ÙÀÌ¿À ÇÁ¸°ÆÃ ½Ã½ºÅÛ°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀº 2022³âºÎÅÍ 2032³â±îÁö ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°èÀÇ ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ ¼¼°è Áö¿ªÀ̸ç, 2023³â À¯·´ÀÌ °¡Àå ±Ô¸ð°¡ Å« Áö¿ª ½ÃÀåÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀº ÀÇ·á¿ë 3D ¹ÙÀÌ¿À ÇÁ¸°ÆÃ Á¦Á¶ ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² 3D Systems Corporation ¹× Organovo Holdings, Inc.¿Í °°Àº ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀº ÀÇ·á ÀÎÇÁ¶ó°¡ Àß ±¸ÃàµÇ¾î ÀÖ°í ¿¬±¸°³¹ß(R&D)¿¡ ¸¹Àº ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖ¾î 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ°ú °°Àº ÷´Ü ±â¼úÀÇ ¹ßÀü°ú äÅÿ¡ µµ¿òÀÌ µÇ´Â ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á¿ë 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ ºÐ¾ßÀÇ Çõ½Å°ú °³Ã´ÀÇ Áß½ÉÁö·Î ÀÚ¸®¸Å±èÇÏ¸ç ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Global 3D Bioprinting in Medical Market is valued approximately at USD 1.27 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.5% over the forecast period 2024-2032. 3D bioprinting in the medical field represents a revolutionary approach to tissue engineering and regenerative medicine. It involves the precise layer-by-layer deposition of biomaterials, cells, and growth factors to create three-dimensional structures that mimic the complex architecture and functionality of native tissues and organs. This cutting-edge technology holds immense promise for a wide range of applications, including organ transplantation, drug screening, disease modeling, and personalized medicine. Global 3D Bioprinting in Medical Market trends towards multi-material and multi-cellular printing which allows the creation of complex tissue structures with heterogeneous compositions. By incorporating different cell types and biomaterials into the printing process, researchers can mimic the diverse microenvironments found in native tissues and organs, enhancing the functionality and biological relevance of the constructs.
The Global 3D Bioprinting in medical Market is experiencing robust growth, propelled by several key factors. The escalating prevalence of chronic diseases, coupled with the pressing need for more accurate models to study disease progression and develop targeted therapies. This is driving the demand for 3D bioprinting in disease modeling and drug testing applications. For instance, significant investments, exceeding USD 300 million, have been granted to Advanced Regenerative Manufacturing Institute (ARMI) by leading manufacturers, universities, nonprofit organizations, and the federal government. This funding aims to foster the development of scalable manufacturing processes for engineered tissues and organs, reflecting the industry's commitment to advancing 3D bioprinting technologies. Furthermore, Global 3D Bioprinting in medical Market is driven by rising advancements in 3D bioprinting technologies and rising spending in medical research and development activities. However, complexity of tissue engineering and high costs associated with 3D bioprinting systems is expected to stifle the market growth between 2022 and 2032.
The key regions considered for the global 3D Bioprinting in Medical market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, Europe was the largest regional market in the market place. The regional market growth is propelled by the presence of key players such as 3D Systems Corporation and Organovo Holdings, Inc., alongside advancements in the manufacturing technology of 3D bioprinting for medical applications. Furthermore, the region has well-established healthcare infrastructure and substantial investment in research and development (R&D), fostering an environment conducive to the advancement and adoption of cutting-edge technologies like 3D bioprinting. These factors collectively drive market growth, positioning the region as a hub for innovation and development in the field of medical 3D bioprinting. The market in Asia Pacific, on the other hand, is expected to grow at the fastest rate over the forecast period.